A citation-based method for searching scientific literature

Veena Sangkhae, S Leah Etheridge, Kenneth Kaushansky, Ian S Hitchcock. Blood 2014
Times Cited: 57



Dongqing Yan, Robert E Hutchison, Golam Mohi. Blood 2012
Times Cited: 97




List of shared articles



Times cited

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Giuseppe G Loscocco, Giacomo Coltro, Paola Guglielmelli, Alessandro M Vannucchi. Cells 2021
2

The Role of Megakaryocytes in Myelofibrosis.
Johanna Melo-Cardenas, Anna Rita Migliaccio, John D Crispino. Hematol Oncol Clin North Am 2021
6


Recent advances in understanding myelofibrosis and essential thrombocythemia.
William Vainchenker, Stefan N Constantinescu, Isabelle Plo. F1000Res 2016
35

Lessons from mouse models of MPN.
Camelia Benlabiod, Tracy Dagher, Caroline Marty, Jean-Luc Villeval. Int Rev Cell Mol Biol 2022
0

Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling.
Therese Vu, Rebecca Austin, Catherine Paine Kuhn, Claudia Bruedigam, Axia Song, Solene Guignes, Sebastien Jacquelin, Hayley S Ramshaw, Geoffrey R Hill, Angel F Lopez,[...]. Haematologica 2016
5

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.
Xavier Cahu, Stefan N Constantinescu. Curr Hematol Malig Rep 2015
14


Pathogenesis of myeloproliferative neoplasms.
Radek C Skoda, Adrian Duek, Jean Grisouard. Exp Hematol 2015
72

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Andrew Dunbar, Abbas Nazir, Ross Levine. Curr Protoc Pharmacol 2017
14

The JAK2 mutation.
Salma Merchant. Int Rev Cell Mol Biol 2021
1